- Home
- ATXG vs MYNZ Comparison
ATXG vs MYNZ Comparison
Compare ATXG & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATXG | MYNZ |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATXG | MYNZ |
|---|---|---|
| Price | $0.27 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 88.9K | ★ 239.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.55 |
| 52 Week High | $1.86 | $5.34 |
Technical Indicators
Market Signals| Indicator | ATXG | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 48.07 |
| Support Level | N/A | $0.57 |
| Resistance Level | $0.49 | $0.94 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 13.04 | 69.44 |
Price Performance
Historical ComparisonAbout ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.